PALO ALTO, Calif., Sept. 10, 2019 /PRNewswire/ -- The New York
Proton Center (NYPC) has treated its first proton therapy cancer
patients. Equipped with the Varian ProBeam® proton
therapy system, NYPC is New York
State's first proton therapy facility and is a collaboration
between Memorial Sloan Kettering Cancer Center, Montefiore Health
System, and Mount Sinai Health System.
NYPC is expected to treat 1,400 patients annually, including
most children in New York City
with solid tumors, delivering the most advanced form of cancer
radiation treatment currently available. Before NYPC was opened,
proton therapy patients in the New
York Metro area were referred to out-of-state
facilities.
"We are thrilled to be delivering the highest standard of
treatment possible and ensuring our patients – many of them
children – are receiving this advanced oncology therapy without
having to travel out of the state," said Dr. Charles B. Simone,II,
FACRO, chief medical officer at the New York Proton Center. "With
the state-of-the-art Varian ProBeam system, we know that our
experienced team of proton therapy experts are able to provide
patients with the most advanced radiation treatment modality
possible."
Proton therapy uses protons, accelerated to about two-thirds the
speed of light, or more than 100,000 miles per second, to destroy
cancer cells, while minimizing exposure to nearby healthy tissues.
NYPC will treat pediatric and adult patients with a wide
variety of conditions, including brain and spine tumors, head and
neck tumors, breast cancer, lung and other thoracic cancers,
gastrointestinal cancers, sarcomas, gynecologic cancers, prostate
cancer, lymphomas and recurrence cancers.
"Seeing our collaboration with long-term strategic partners in
radiation oncology at New York Proton Center come to fruition is a
very proud moment for Varian," said Kolleen
Kennedy, president, Proton Solutions and chief growth
officer at Varian. "This means the most advanced cancer care for
patients in the greater New York
area, and we are excited to build upon this strong foundation
as we partner to deliver on the promise of a world without fear of
cancer."
About the New York Proton Center
The New York Proton Center is creating the gold standard for
proton therapy, giving new hope to patients living with cancer. In
partnership with leading academic medical centers—Memorial Sloan
Kettering Cancer Center, Montefiore Health System, Mount Sinai
Health System, and ProHEALTH as manager—the New York Proton Center
brings together expert oncologists, clinical care teams, and
researchers to improve cancer care and advance the clinical
evidence for proton therapy. For additional information, please
visit www.nyproton.com.
About Varian
At Varian (NYSE: VAR), we envision a world without fear of
cancer. For more than 70 years, we have developed, built and
delivered innovative cancer care technologies and solutions for our
clinical partners around the globe to help them treat millions of
patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 9,200 employees across 70 countries keep
the patient and our clinical partners at the center of our thinking
as we power new victories in cancer care. Because, for cancer
patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow
@VarianMedSys on Twitter.
Press Contact
Mark Plungy
Director, Public Relations
+1 (650) 424-5630
mark.plungy@varian.com
Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-equipped-new-york-proton-therapy-center-treats-first-patients-300914937.html
SOURCE Varian